Company intelligence / Profile preview

Univercells Technologies

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Univercells Technologies develops and commercializes innovative biomanufacturing technologies—most notably the scale-X™ single-use fixed-bed bioreactor and NevoLine™ automated upstream platform—to enable cost-effective production of viral vectors and vaccines from R&D through commercial scales. Their solutions are widely adopted in cell & gene therapy as well as vaccine manufacturing. The company was acquired by Donaldson Company in June 2023 to expand Donaldson’s life sciences portfolio.

Modalities: Device (bioreactors)Platform technology for viral vector and vaccine production (enabling Cell therapy, Gene therapy, Viral vaccines)
Industry: Non-Drug Biotech

Partnerships

Key partnerships include collaborations with CDMOs such as Exothera and VIVEBiotech who use their platforms for cell & gene therapy vector production. No major pharma co-development deals disclosed.

Beyond the preview

Go deeper on Univercells Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univercells Technologies.